Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer : A multiinstitutional phase 2 study

The purpose was to determine the efficacy and toxicity of irinotecan and cisplatin with concurrent split-course thoracic radiotherapy (TRT) in locally advanced nonsmall-cell lung cancer. Fifty patients fulfilling the following eligibility criteria were enrolled: chemotherapy-naive, good performance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2007-08, Vol.110 (3), p.606-613
Hauptverfasser:	FUKUDA, Minoru, SODA, Hiroshi, FUKUDA, Masaaki, KINOSHITA, Akitoshi, NAKAMURA, Yoichi, NAGASHIMA, Seiji, TAKATANI, Hiroshi, TSUKAMOTO, Kazuhiro, KOHNO, Shigeru, OKA, Mikio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - analogs & derivatives Carcinoma, Large Cell - drug therapy Carcinoma, Large Cell - pathology Carcinoma, Large Cell - radiotherapy Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - radiotherapy Carcinoma, Non-Small-Cell Lung - therapy Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Cisplatin - administration & dosage Combined Modality Therapy Disease-Free Survival Female Humans Japan Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Lung Neoplasms - therapy Male Medical sciences Middle Aged Neoplasm Staging Pneumology Radiotherapy Dosage Survival Rate Treatment Outcome Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!